Brand Name

Effexor

Generic Name
Venlafaxine
View Brand Information
FDA approval date: November 01, 1997
Classification: Serotonin and Norepinephrine Reuptake Inhibitor
Form: Tablet, Capsule

What is Effexor (Venlafaxine)?

Effexor (venlafaxine) is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant that works by affecting the balance of neurotransmitters in the brain. The medication has received FDA approval for several mental health conditions and is one of the more widely prescribed antidepressants in its class. 

Primary FDA-approved uses include:  

  • Major Depressive Disorder (MDD)  
  • Generalized Anxiety Disorder (GAD)  
  • Social Anxiety Disorder (SAD)  
  • Panic Disorder with or without agoraphobia 

Healthcare providers may also prescribe Effexor “off-label” for other conditions, including:  

  • Hot flashes associated with menopause  
  • Diabetic neuropathy  
  • Posttraumatic stress disorder (PTSD)  
  • Obsessive-compulsive disorder (OCD) 

The medication works by increasing the levels of both serotonin and norepinephrine in the brain, which helps improve mood, reduce anxiety, and restore interest in daily activities. Unlike some other antidepressants, Effexor’s dual action on both neurotransmitters can make it particularly effective for patients who haven’t responded well to other antidepressant medications. 

What are the side effects of Effexor? 

Effexor can cause a range of side effects, from mild to severe, and it’s important for patients to be aware of these potential effects. Common side effects typically appear within the first few weeks of treatment and may diminish over time as the body adjusts to the medication. 

Common side effects include:  

  • Nausea and vomiting  
  • Headache  
  • Sleep problems (insomnia or unusual dreams)  
  • Dry mouth  
  • Dizziness  
  • Sweating  
  • Sexual dysfunction  
  • Loss of appetite  
  • Constipation  
  • Fatigue 

More serious side effects that require immediate medical attention:  

  • Increased blood pressure  
  • Serotonin syndrome  
  • Acute angle-closure glaucoma  
  • Unusual bleeding or bruising  
  • Seizures  
  • Hyponatremia (low sodium levels)  
  • Increased suicidal thoughts, particularly in young adults 

Effexor carries a black box warning (the FDA’s strongest warning) regarding an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults. Regular monitoring by a healthcare provider is essential, especially during the first few months of treatment or after dose adjustments. 

One particularly important consideration with Effexor is its discontinuation syndrome. Stopping the medication abruptly can lead to severe withdrawal symptoms, including:  

  • Brain zaps (electric shock sensations)  
  • Dizziness and vertigo  
  • Nausea and vomiting  
  • Irritability  
  • Anxiety and agitation  
  • Sensory disturbances 

Is there a generic drug version of Effexor? 

Yes, generic versions of Effexor (venlafaxine) are widely available and have been FDA-approved since 2006. The generic is available in both immediate-release (IR) and extended-release (XR) formulations, making it a more cost-effective option for many patients. Generic venlafaxine is considered therapeutically equivalent to brand-name Effexor and contains the same active ingredient. 

The availability of generic versions has significantly reduced treatment costs, as generic medications typically cost substantially less than their brand-name counterparts. While the active ingredient remains the same, generic versions may contain different inactive ingredients, which rarely can affect how individual patients respond to the medication. Most patients transition seamlessly between brand-name and generic versions, though some may notice slight differences in side effects or effectiveness. 

Effexor Dosage Information 

Effexor dosing varies depending on the condition being treated, the formulation being used (IR or XR), and individual patient factors. The medication is available in multiple strengths, and dosing typically starts low and increases gradually to minimize side effects. 

For Major Depressive Disorder:  

  • Starting dose: 37.5-75 mg/day  
  • Usual target dose: 150-225 mg/day  
  • Maximum dose: 375 mg/day 

For Generalized Anxiety Disorder:  

  • Starting dose: 37.5-75 mg/day  
  • Usual target dose: 75-225 mg/day  
  • Maximum dose: 225 mg/day 

For Social Anxiety Disorder:  

  • Starting dose: 75 mg/day  
  • Usual maintenance dose: 75 mg/day  
  • Maximum dose: 75 mg/day 

Important dosing considerations include: 

Administration Guidelines:  

  • Take at the same time each day  
  • Extended-release capsules should be taken with food  
  • Capsules should be swallowed whole, not crushed or chewed  
  • If using extended-release capsules, they can be carefully opened and sprinkled on applesauce if needed 

Special Populations:  

  • Elderly patients may require lower doses  
  • Patients with liver or kidney problems may need dose adjustments  
  • Gradual dose reduction is essential when discontinuing 

Healthcare providers will determine the most appropriate starting dose and adjust based on response and tolerability. Regular monitoring of blood pressure is important, as Effexor can cause hypertension in some patients. Any dose changes should be made under medical supervision to minimize the risk of discontinuation symptoms or other adverse effects. 

The medication should be stored at room temperature, away from moisture and heat. Patients should never adjust their dose or stop taking Effexor without consulting their healthcare provider, as this can lead to severe withdrawal symptoms. Regular follow-up appointments are essential to monitor progress and address any concerns that may arise during treatment. 

Approved To Treat

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

There is no latest advances for this treatment

Brand Information

Effexor (VENLAFAXINE HYDROCHLORIDE)
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors Warnings and Precautions (5.1)]. Effexor XR is not approved for use in pediatric patients Use in Specific Populations (8.4)].
1INDICATIONS AND USAGE
Effexor XR is indicated in adults for the treatment of:
  • Major Depressive Disorder (MDD)
  • Generalized Anxiety Disorder (GAD)
  • Social Anxiety Disorder (SAD)
  • Panic Disorder (PD)
2DOSAGE FORMS AND STRENGTHS
Effexor XR
  • 37.5 mg extended-release capsule: grey cap and peach body with "W" and "Effexor XR" on the cap and "37.5" on the body
  • 75 mg extended-release capsule: peach cap and body with "W" and "Effexor XR" on the cap and "75" on the body
  • 150 mg extended-release capsule: dark orange cap and body with "W" and "Effexor XR" on the cap and "150" on the body
3CONTRAINDICATIONS
Effexor XR is contraindicated in patients:
  • with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation
  • taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome
4ADVERSE REACTIONS
The following adverse reactions are discussed in more detail in other sections of the labeling:
  • Hypersensitivity
  • Suicidal Thoughts and Behaviors in Adolescents and Young Adults
  • Serotonin Syndrome
  • Elevated Blood Pressure
  • Increased Risk of Bleeding
  • Angle-Closure Glaucoma
  • Activation of Mania/Hypomania
  • Discontinuation Syndrome
  • Seizure
  • Hyponatremia
  • Weight and Height changes in Pediatric Patients
  • Appetite Changes in Pediatric Patients
  • Interstitial Lung Disease and Eosinophilic Pneumonia
  • Sexual Dysfunction
4.1Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
4.2Postmarketing Experience
The following adverse reactions have been identified during post-approval use of Effexor XR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Body as a whole – Anaphylaxis, angioedema
Cardiovascular system – QT prolongation, ventricular fibrillation, ventricular tachycardia (including torsade de pointes), takotsubo cardiomyopathy
Digestive system – Pancreatitis
Hemic/Lymphatic system – Mucous membrane bleeding [see , blood dyscrasias (including agranulocytosis, aplastic anemia, neutropenia and pancytopenia), prolonged bleeding time, thrombocytopenia
Metabolic/Nutritional – Hyponatremia [see , Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion [see , abnormal liver function tests, hepatitis, prolactin increased
Musculoskeletal – Rhabdomyolysis
Nervous system – Neuroleptic Malignant Syndrome (NMS) [see , serotonergic syndrome [see , delirium, extrapyramidal reactions (including dystonia and dyskinesia), impaired coordination and balance, tardive dyskinesia
Respiratory system – Dyspnea, interstitial lung disease, pulmonary eosinophilia [see
Skin and appendages – Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
Special senses – Angle-closure glaucoma [see
5DESCRIPTION
Effexor XR is an extended-release capsule for once-a-day oral administration that contains venlafaxine hydrochloride, a serotonin and norepinephrine reuptake inhibitor (SNRI).
Venlafaxine is designated (R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[α- [(dimethylamino)methyl]-p-methoxybenzyl] cyclohexanol hydrochloride and has the empirical formula of C
Chemical Structure
Venlafaxine hydrochloride is a white to off-white crystalline solid, with a solubility of 572 mg/mL in water (adjusted to ionic strength of 0.2 M with sodium chloride). Its octanol:water (0.2 M sodium chloride) partition coefficient is 0.43.
Drug release is controlled by diffusion through the coating membrane on the spheroids and is not pH-dependent. Capsules contain venlafaxine hydrochloride equivalent to 37.5 mg, 75 mg, or 150 mg venlafaxine. Inactive ingredients consist of cellulose, ethylcellulose, gelatin, hypromellose, iron oxide, and titanium dioxide.
6HOW SUPPLIED/STORAGE AND HANDLING
Effexor XR
  • 37.5 mg, grey cap/peach body with "W" and "Effexor XR" on the cap and "37.5" on the body.
  • 75 mg, peach cap and body with "W" and "Effexor XR" on the cap and "75" on the body.
  • 150 mg, dark orange cap and body with "W" and "Effexor XR" on the cap and "150" on the body.
7PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
8PRINCIPAL DISPLAY PANEL - 37.5 mg Capsule Bottle Label
ALWAYS DISPENSE WITH MEDICATION GUIDE
Pfizer
Effexor XR
37.5 mg*
30 Capsules
Principal Display Panel - 37.5 mg Capsule Bottle Label
9PRINCIPAL DISPLAY PANEL - 37.5 mg Capsule Blister Pack
Effexor XR
(venlafaxine HCl)
Extended-Release Capsules
37.5 mg
Wyeth
Principal Display Panel - 37.5 mg Capsule Blister Pack
10PRINCIPAL DISPLAY PANEL - 37.5 mg Capsule Blister Pack Carton
ALWAYS DISPENSE WITH MEDICATION GUIDE
NDC 0008-0837-03
Pfizer
Effexor XR®
(venlafaxine HCl)
Extended-Release Capsules
37.5 mg*
10 Redipak
Rx only
Principal Display Panel - 37.5 mg Capsule Blister Pack Carton
11PRINCIPAL DISPLAY PANEL - 75 mg Capsule Bottle Label
ALWAYS DISPENSE WITH MEDICATION GUIDE
NDC 0008-0833-21
Pfizer
Effexor XR
75 mg*
30 Capsules
Principal Display Panel - 75 mg Capsule Bottle Label
12PRINCIPAL DISPLAY PANEL - 75 mg Capsule Blister Pack
Effexor XR
(venlafaxine HCl)
Extended-Release Capsules
75 mg
Wyeth
Principal Display Panel - 75 mg Capsule Blister Pack
13PRINCIPAL DISPLAY PANEL - 75 mg Capsule Blister Pack Carton
ALWAYS DISPENSE WITH MEDICATION GUIDE
NDC 0008-0833-03
Pfizer
Effexor XR®
(venlafaxine HCl)
Extended-Release Capsules
75 mg*
10 Redipak
Rx only
Principal Display Panel - 75 mg Capsule Blister Pack Carton
14PRINCIPAL DISPLAY PANEL - 150 mg Capsule Bottle Label
ALWAYS DISPENSE WITH MEDICATION GUIDE
NDC 0008-0836-21
Pfizer
Effexor XR
150 mg*
30 Capsules
Principal Display Panel - 150 mg Capsule Bottle Label
15PRINCIPAL DISPLAY PANEL - 150 mg Capsule Blister Pack
Effexor XR
(venlafaxine HCl)
Extended-Release Capsules
150 mg
Wyeth
Principal Display Panel - 150 mg Capsule Blister Pack
16PRINCIPAL DISPLAY PANEL - 150 mg Capsule Blister Pack Carton
ALWAYS DISPENSE WITH MEDICATION GUIDE
NDC 0008-0836-03
Pfizer
Effexor XR
(venlafaxine HCl)
Extended-Release Capsules
150 mg*
10 Redipak
Rx only
Principal Display Panel - 150 mg Capsule Blister Pack Carton